London | Reuters — European drug regulators launched a review on Jan. 11 of the use in farming of a key last-line antibiotic called colistin, after international research found alarming evidence of a gene that makes bacteria resistant to the drug. The London-based European Medicines Agency (EMA) said it was responding to a European Commission